Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis

This publication has 26 references indexed in Scilit:

• Getting to know the enemy better—the global burden of chronic kidney disease
  Kidney International, 2018
• Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison
  Heart Failure Reviews, 2018
• True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis
  American Heart Journal, 2017
• A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
  Journal of Diabetes and its Complications, 2017
• A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
  European Heart Journal, 2016
• A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease
  Circulation Journal, 2016
• Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
  JAMA, 2015
• Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases
  Hypertension, 2015
• Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
  European Heart Journal, 2013
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
  New England Journal of Medicine, 1999